Drug interactions between Coumadin and Zantac 150 EFFERdose
| Results for the following 2 drugs: |
|---|
| Coumadin (warfarin) |
| Zantac 150 EFFERdose (ranitidine) |
Interactions between your selected drugs
ranitidine ↔ warfarin
Applies to:Zantac 150 EFFERdose (ranitidine) and Coumadin (warfarin)
MONITOR: Limited data suggest that ranitidine may occasionally alter the hypoprothrombinemic effect of coumarin anticoagulants. There have been rare reports of altered prothrombin time or INR (both increases and decreases) during coadministration of ranitidine and warfarin. The mechanism of interaction is unknown. Ranitidine at usual therapeutic dosages has not been shown to significantly affect CYP450-mediated metabolism. Ranitidine also did not alter the pharmacokinetics or pharmacodynamics of warfarin in three out of four interaction studies. In the fourth study, oral clearance of a single dose of warfarin was reduced by 27% in five healthy subjects given ranitidine 150 mg twice a day for 7 days, and by more than 50% in two subjects given ranitidine 750 mg daily.
MANAGEMENT: Until more data are available, caution may be advisable if ranitidine is used in combination with coumarin anticoagulants. The INR should be checked regularly and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of ranitidine in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
See also...
- Zantac 150 EFFERdose Drug Interactions
- Zantac 150 EFFERdose Effervescent Tablets General Consumer Information
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
